Key result
Exon skipping is a promising molecular treatment approach for Duchenne muscular dystrophy that aims to initiate dystrophin production, though more accumulating data is still needed.
Why the study?
Although some exon skipping molecules have received conditional approval for Duchenne muscular dystrophy, accumulating data are still needed.
Do exon skipping therapies improve clinical outcomes in patients with Duchenne muscular dystrophy?
Do exon skipping therapies improve clinical outcomes in patients with Duchenne muscular dystrophy?
Exon skipping is an established and evolving molecular treatment approach for Duchenne muscular dystrophy that aims to initiate dystrophin production and alter disease progression.
Conditional approvals warrant outcome confirmation before routine use; leaves open clinical benefit in Duchenne muscular dystrophy.
Molecular treatments for Duchenne muscular dystrophy (DMD) are already in clinical practice. One particular means is exon skipping, an approach which has more than 15 years of background. There are several promising clinical trials based on earlier works. The aim is to be able to initiate the production of enough dystrophin to change the rate of progression and create a clinical shift towards the better. Some of these molecules already have received at least conditional approval by health authorities; however, we still need new accumulating data.
No takes yet. Share an insight, caveat, or question.
Eser et al. (2022) conducted a review in Duchenne muscular dystrophy (DMD). Exon skipping was evaluated. Exon skipping is a promising molecular treatment approach for Duchenne muscular dystrophy that aims to initiate dystrophin production, though more accumulating data is still needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: